Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acute Kidney Injury | 57 | 2024 | 1946 | 9.560 |
Why?
|
Fibroblast Growth Factors | 14 | 2020 | 871 | 3.090 |
Why?
|
Critical Illness | 30 | 2023 | 2744 | 2.170 |
Why?
|
Renal Replacement Therapy | 12 | 2023 | 281 | 1.890 |
Why?
|
Cardiac Surgical Procedures | 12 | 2021 | 3675 | 1.490 |
Why?
|
Intensive Care Units | 23 | 2022 | 3800 | 1.310 |
Why?
|
Iron | 7 | 2023 | 1816 | 1.270 |
Why?
|
Kidney | 15 | 2024 | 7066 | 0.950 |
Why?
|
Cisplatin | 4 | 2024 | 1658 | 0.950 |
Why?
|
Nephritis, Interstitial | 4 | 2024 | 158 | 0.860 |
Why?
|
Kidney Calculi | 3 | 2013 | 457 | 0.860 |
Why?
|
Anemia, Hemolytic, Autoimmune | 3 | 2021 | 147 | 0.850 |
Why?
|
Platelet Factor 4 | 1 | 2023 | 132 | 0.850 |
Why?
|
Vitamins | 4 | 2022 | 1630 | 0.850 |
Why?
|
Calcitriol | 2 | 2014 | 299 | 0.830 |
Why?
|
Hospital Mortality | 21 | 2022 | 5343 | 0.810 |
Why?
|
Vitamin D | 10 | 2021 | 3272 | 0.780 |
Why?
|
Ritonavir | 1 | 2023 | 330 | 0.730 |
Why?
|
Diphenhydramine | 1 | 2021 | 61 | 0.720 |
Why?
|
Dialysis Solutions | 1 | 2020 | 33 | 0.680 |
Why?
|
Renal Insufficiency, Chronic | 8 | 2023 | 2310 | 0.670 |
Why?
|
Hemoglobins | 4 | 2019 | 1530 | 0.660 |
Why?
|
Critical Care | 7 | 2021 | 2712 | 0.660 |
Why?
|
Cardiopulmonary Bypass | 4 | 2020 | 1090 | 0.640 |
Why?
|
Creatinine | 8 | 2024 | 1915 | 0.630 |
Why?
|
Peritoneal Dialysis | 1 | 2020 | 161 | 0.620 |
Why?
|
Hyperkalemia | 2 | 2023 | 233 | 0.620 |
Why?
|
Iron Chelating Agents | 1 | 2019 | 142 | 0.610 |
Why?
|
Thrombotic Microangiopathies | 2 | 2018 | 125 | 0.600 |
Why?
|
Sepsis | 4 | 2020 | 2606 | 0.590 |
Why?
|
ABO Blood-Group System | 1 | 2020 | 380 | 0.580 |
Why?
|
Kidney Diseases | 2 | 2024 | 2098 | 0.580 |
Why?
|
Mesothelioma | 1 | 2023 | 771 | 0.560 |
Why?
|
Glucuronidase | 1 | 2019 | 203 | 0.560 |
Why?
|
Minerals | 1 | 2019 | 278 | 0.560 |
Why?
|
Hypocalcemia | 1 | 2019 | 205 | 0.550 |
Why?
|
Hyperphosphatemia | 2 | 2019 | 38 | 0.550 |
Why?
|
Humans | 129 | 2024 | 765956 | 0.550 |
Why?
|
Cation Exchange Resins | 1 | 2016 | 19 | 0.530 |
Why?
|
Causality | 1 | 2022 | 1248 | 0.530 |
Why?
|
Vitamin D Deficiency | 2 | 2019 | 1348 | 0.520 |
Why?
|
Polystyrenes | 1 | 2016 | 102 | 0.510 |
Why?
|
Cholecalciferol | 1 | 2021 | 550 | 0.510 |
Why?
|
Antimicrobial Cationic Peptides | 2 | 2015 | 348 | 0.510 |
Why?
|
Glomerular Filtration Rate | 8 | 2024 | 2233 | 0.500 |
Why?
|
Tissue Plasminogen Activator | 1 | 2021 | 1167 | 0.500 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2024 | 2024 | 0.500 |
Why?
|
Heme Oxygenase-1 | 1 | 2016 | 364 | 0.440 |
Why?
|
Organ Transplantation | 2 | 2021 | 1174 | 0.440 |
Why?
|
Kidney Glomerulus | 2 | 2020 | 568 | 0.440 |
Why?
|
24,25-Dihydroxyvitamin D 3 | 1 | 2013 | 8 | 0.430 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2021 | 1002 | 0.430 |
Why?
|
Middle Aged | 62 | 2024 | 223004 | 0.420 |
Why?
|
Osteomalacia | 1 | 2013 | 60 | 0.410 |
Why?
|
Aged | 55 | 2024 | 171114 | 0.410 |
Why?
|
Fluorobenzenes | 1 | 2014 | 179 | 0.400 |
Why?
|
Unnecessary Procedures | 1 | 2016 | 416 | 0.390 |
Why?
|
Hydrocephalus, Normal Pressure | 1 | 2013 | 101 | 0.390 |
Why?
|
Parathyroid Hormone | 6 | 2019 | 1789 | 0.390 |
Why?
|
Lateral Ventricles | 1 | 2013 | 142 | 0.390 |
Why?
|
Vitamin D-Binding Protein | 1 | 2013 | 129 | 0.390 |
Why?
|
Postoperative Complications | 6 | 2020 | 15747 | 0.390 |
Why?
|
Kidney Transplantation | 4 | 2024 | 4270 | 0.380 |
Why?
|
Female | 75 | 2024 | 396101 | 0.370 |
Why?
|
Laxatives | 1 | 2012 | 94 | 0.370 |
Why?
|
Ergocalciferols | 1 | 2012 | 105 | 0.370 |
Why?
|
Male | 73 | 2024 | 363691 | 0.360 |
Why?
|
Kidney Function Tests | 4 | 2020 | 683 | 0.360 |
Why?
|
Hypercalciuria | 1 | 2010 | 31 | 0.360 |
Why?
|
Cefoxitin | 1 | 2010 | 36 | 0.360 |
Why?
|
Medical Order Entry Systems | 1 | 2016 | 521 | 0.360 |
Why?
|
Cerebral Ventricles | 1 | 2013 | 549 | 0.350 |
Why?
|
Nephrolithiasis | 1 | 2012 | 121 | 0.350 |
Why?
|
Neoplasms | 6 | 2024 | 22340 | 0.340 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2023 | 5753 | 0.340 |
Why?
|
Drug Monitoring | 1 | 2016 | 962 | 0.340 |
Why?
|
Nurse-Patient Relations | 1 | 2010 | 102 | 0.330 |
Why?
|
Anemia, Hemolytic | 1 | 2010 | 164 | 0.330 |
Why?
|
Facility Design and Construction | 1 | 2010 | 88 | 0.320 |
Why?
|
Urokinase-Type Plasminogen Activator | 2 | 2020 | 323 | 0.320 |
Why?
|
Rhabdomyolysis | 1 | 2009 | 151 | 0.300 |
Why?
|
Respiratory Insufficiency | 3 | 2021 | 1240 | 0.300 |
Why?
|
Sinoatrial Node | 1 | 2008 | 99 | 0.300 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6547 | 0.290 |
Why?
|
Immunologic Factors | 2 | 2017 | 1587 | 0.290 |
Why?
|
Risk Factors | 23 | 2024 | 74836 | 0.290 |
Why?
|
Immunotherapy | 3 | 2021 | 4752 | 0.290 |
Why?
|
Standard of Care | 2 | 2021 | 567 | 0.280 |
Why?
|
Research Design | 1 | 2022 | 6208 | 0.270 |
Why?
|
Pregnancy Complications | 1 | 2021 | 2971 | 0.270 |
Why?
|
Hydrocephalus | 1 | 2013 | 762 | 0.260 |
Why?
|
Connexins | 1 | 2008 | 356 | 0.260 |
Why?
|
Acetazolamide | 1 | 2006 | 98 | 0.260 |
Why?
|
Carbonic Anhydrase Inhibitors | 1 | 2006 | 93 | 0.260 |
Why?
|
Polymorphism, Genetic | 1 | 2016 | 4247 | 0.250 |
Why?
|
Cystatin C | 2 | 2024 | 272 | 0.250 |
Why?
|
Altitude Sickness | 1 | 2006 | 93 | 0.250 |
Why?
|
Adult | 38 | 2024 | 223038 | 0.250 |
Why?
|
Cohort Studies | 19 | 2024 | 41647 | 0.230 |
Why?
|
Cathelicidins | 2 | 2015 | 81 | 0.230 |
Why?
|
Sulfonamides | 1 | 2014 | 1984 | 0.230 |
Why?
|
Retrospective Studies | 22 | 2024 | 81515 | 0.230 |
Why?
|
Brain Diseases | 1 | 2013 | 1546 | 0.220 |
Why?
|
Risk Assessment | 5 | 2024 | 24283 | 0.220 |
Why?
|
Ferritins | 2 | 2019 | 600 | 0.220 |
Why?
|
Anemia, Iron-Deficiency | 2 | 2019 | 374 | 0.220 |
Why?
|
Renal Dialysis | 4 | 2023 | 1799 | 0.220 |
Why?
|
Incidence | 10 | 2024 | 21480 | 0.220 |
Why?
|
Prone Position | 2 | 2021 | 201 | 0.210 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 2 | 2020 | 74 | 0.210 |
Why?
|
Calcium | 2 | 2017 | 5767 | 0.210 |
Why?
|
Clinical Trials as Topic | 2 | 2016 | 8041 | 0.200 |
Why?
|
Receptors, Interleukin-6 | 2 | 2021 | 226 | 0.200 |
Why?
|
Oxygen | 2 | 2021 | 4241 | 0.200 |
Why?
|
Hemochromatosis | 1 | 2023 | 175 | 0.200 |
Why?
|
Pyrimidines | 1 | 2014 | 3047 | 0.200 |
Why?
|
Phosphates | 3 | 2016 | 763 | 0.200 |
Why?
|
Transferrin | 2 | 2023 | 283 | 0.200 |
Why?
|
Fibrin Fibrinogen Degradation Products | 2 | 2021 | 428 | 0.190 |
Why?
|
Educational Measurement | 1 | 2009 | 1260 | 0.190 |
Why?
|
Bilirubin | 1 | 2023 | 439 | 0.190 |
Why?
|
Patient Positioning | 2 | 2021 | 328 | 0.190 |
Why?
|
Prospective Studies | 11 | 2020 | 54806 | 0.190 |
Why?
|
Bradycardia | 1 | 2023 | 302 | 0.190 |
Why?
|
Kidney Tubules | 2 | 2020 | 453 | 0.190 |
Why?
|
Iron Overload | 1 | 2023 | 245 | 0.190 |
Why?
|
Kidney Failure, Chronic | 2 | 2017 | 2495 | 0.190 |
Why?
|
Antineoplastic Agents | 3 | 2023 | 13648 | 0.180 |
Why?
|
Pandemics | 7 | 2022 | 8701 | 0.180 |
Why?
|
United States | 20 | 2024 | 72898 | 0.180 |
Why?
|
Colonic Neoplasms | 1 | 2013 | 2531 | 0.180 |
Why?
|
Heart Arrest | 2 | 2021 | 1516 | 0.180 |
Why?
|
Treatment Outcome | 11 | 2023 | 65189 | 0.180 |
Why?
|
Program Evaluation | 1 | 2009 | 2499 | 0.170 |
Why?
|
Antibodies, Monoclonal | 2 | 2020 | 9249 | 0.170 |
Why?
|
Antiviral Agents | 2 | 2023 | 3050 | 0.170 |
Why?
|
Dexamethasone | 2 | 2020 | 1963 | 0.170 |
Why?
|
Immunotherapy, Adoptive | 2 | 2020 | 1510 | 0.170 |
Why?
|
Oxygen Consumption | 1 | 2006 | 1870 | 0.170 |
Why?
|
Glycerophosphates | 1 | 2020 | 51 | 0.170 |
Why?
|
Iatrogenic Disease | 1 | 2023 | 553 | 0.170 |
Why?
|
Medical Futility | 1 | 2021 | 136 | 0.170 |
Why?
|
Magnesium | 1 | 2023 | 813 | 0.170 |
Why?
|
Education, Medical, Undergraduate | 1 | 2009 | 1085 | 0.170 |
Why?
|
Hemorrhage | 3 | 2021 | 3461 | 0.170 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 3251 | 0.160 |
Why?
|
Retroperitoneal Space | 1 | 2020 | 173 | 0.160 |
Why?
|
Aged, 80 and over | 13 | 2021 | 59488 | 0.160 |
Why?
|
Severity of Illness Index | 7 | 2021 | 15880 | 0.160 |
Why?
|
Prednisone | 2 | 2017 | 1565 | 0.160 |
Why?
|
Intraoperative Care | 2 | 2021 | 760 | 0.160 |
Why?
|
Resuscitation Orders | 1 | 2021 | 275 | 0.160 |
Why?
|
Sarcopenia | 1 | 2024 | 378 | 0.160 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2020 | 110 | 0.160 |
Why?
|
Anemia | 1 | 2008 | 1511 | 0.160 |
Why?
|
Sodium | 2 | 2016 | 1591 | 0.150 |
Why?
|
Length of Stay | 5 | 2021 | 6485 | 0.150 |
Why?
|
Arrhythmias, Cardiac | 1 | 2008 | 2247 | 0.150 |
Why?
|
Renin-Angiotensin System | 1 | 2023 | 737 | 0.150 |
Why?
|
Health Care Rationing | 1 | 2021 | 436 | 0.150 |
Why?
|
Glucocorticoids | 2 | 2019 | 2132 | 0.150 |
Why?
|
Comorbidity | 6 | 2021 | 10563 | 0.150 |
Why?
|
Vomiting | 1 | 2021 | 647 | 0.140 |
Why?
|
Biosynthetic Pathways | 1 | 2018 | 138 | 0.140 |
Why?
|
Hospitals | 2 | 2021 | 3888 | 0.140 |
Why?
|
Blood Coagulation Disorders | 1 | 2021 | 349 | 0.140 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2019 | 10383 | 0.140 |
Why?
|
Students, Dental | 1 | 2019 | 170 | 0.140 |
Why?
|
Comparative Effectiveness Research | 1 | 2022 | 714 | 0.140 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2021 | 418 | 0.140 |
Why?
|
Salivary Proteins and Peptides | 1 | 2017 | 48 | 0.140 |
Why?
|
Patients | 1 | 2024 | 910 | 0.140 |
Why?
|
Interferon Regulatory Factor-2 | 1 | 2017 | 21 | 0.140 |
Why?
|
Hyperparathyroidism | 1 | 2019 | 337 | 0.140 |
Why?
|
Glomerulosclerosis, Focal Segmental | 1 | 2020 | 333 | 0.140 |
Why?
|
Pilot Projects | 3 | 2023 | 8733 | 0.140 |
Why?
|
Natural Killer T-Cells | 1 | 2020 | 319 | 0.140 |
Why?
|
Internet | 1 | 2009 | 3106 | 0.140 |
Why?
|
Thrombosis | 2 | 2021 | 2949 | 0.140 |
Why?
|
Heparin | 1 | 2023 | 1630 | 0.130 |
Why?
|
Blood Protein Electrophoresis | 1 | 2016 | 65 | 0.130 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2023 | 1061 | 0.130 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1514 | 0.130 |
Why?
|
Arteriosclerosis | 1 | 2020 | 1053 | 0.130 |
Why?
|
Cryoglobulins | 1 | 2016 | 58 | 0.130 |
Why?
|
Prognosis | 5 | 2021 | 29921 | 0.130 |
Why?
|
Respiration, Artificial | 3 | 2023 | 2709 | 0.130 |
Why?
|
Hepatitis E | 1 | 2017 | 76 | 0.130 |
Why?
|
Glomerulonephritis, Membranous | 1 | 2017 | 84 | 0.130 |
Why?
|
Substance-Related Disorders | 1 | 2012 | 4415 | 0.120 |
Why?
|
Antibodies | 1 | 2023 | 2417 | 0.120 |
Why?
|
Transplantation Conditioning | 2 | 2023 | 1635 | 0.120 |
Why?
|
Nephrectomy | 1 | 2020 | 927 | 0.120 |
Why?
|
Complement C4 | 1 | 2016 | 208 | 0.120 |
Why?
|
Pleural Neoplasms | 1 | 2020 | 581 | 0.120 |
Why?
|
Adenocarcinoma | 1 | 2013 | 6364 | 0.120 |
Why?
|
Myocardium | 1 | 2008 | 4760 | 0.120 |
Why?
|
Fibrosis | 2 | 2020 | 2070 | 0.120 |
Why?
|
Logistic Models | 4 | 2020 | 13266 | 0.120 |
Why?
|
Multivariate Analysis | 3 | 2013 | 12057 | 0.120 |
Why?
|
Erythropoietin | 1 | 2019 | 716 | 0.120 |
Why?
|
Apolipoproteins | 1 | 2017 | 327 | 0.120 |
Why?
|
Triage | 1 | 2021 | 996 | 0.120 |
Why?
|
Erythrocyte Transfusion | 2 | 2021 | 568 | 0.110 |
Why?
|
Urine | 1 | 2016 | 360 | 0.110 |
Why?
|
NAD | 1 | 2018 | 619 | 0.110 |
Why?
|
T-Box Domain Proteins | 1 | 2017 | 469 | 0.110 |
Why?
|
Kidney Neoplasms | 2 | 2021 | 4274 | 0.110 |
Why?
|
Blood Coagulation | 1 | 2020 | 1166 | 0.110 |
Why?
|
Biopsy | 2 | 2016 | 6763 | 0.110 |
Why?
|
Acid-Base Equilibrium | 1 | 2015 | 180 | 0.110 |
Why?
|
Adiposity | 1 | 2024 | 1890 | 0.110 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 2016 | 283 | 0.110 |
Why?
|
Lipocalins | 1 | 2015 | 162 | 0.110 |
Why?
|
Complement C3 | 1 | 2016 | 424 | 0.110 |
Why?
|
Hospital Design and Construction | 1 | 2014 | 34 | 0.110 |
Why?
|
Patients' Rooms | 1 | 2014 | 63 | 0.110 |
Why?
|
Acute-Phase Proteins | 1 | 2015 | 252 | 0.110 |
Why?
|
Urinalysis | 1 | 2016 | 368 | 0.110 |
Why?
|
Erythropoiesis | 1 | 2017 | 691 | 0.110 |
Why?
|
Urea | 1 | 2016 | 448 | 0.110 |
Why?
|
APACHE | 2 | 2014 | 268 | 0.110 |
Why?
|
Blood Loss, Surgical | 1 | 2017 | 629 | 0.110 |
Why?
|
Survival Rate | 5 | 2021 | 12795 | 0.110 |
Why?
|
Proteinuria | 1 | 2016 | 607 | 0.100 |
Why?
|
Time Factors | 6 | 2017 | 40065 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3100 | 0.100 |
Why?
|
Catalysis | 1 | 2014 | 770 | 0.100 |
Why?
|
Animals | 12 | 2020 | 168759 | 0.100 |
Why?
|
Algorithms | 3 | 2021 | 14071 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3223 | 0.100 |
Why?
|
Lipoproteins, HDL | 1 | 2017 | 674 | 0.100 |
Why?
|
Hypophosphatemia | 1 | 2013 | 92 | 0.100 |
Why?
|
Injections, Intravenous | 1 | 2014 | 1377 | 0.100 |
Why?
|
Anti-Bacterial Agents | 1 | 2010 | 7478 | 0.100 |
Why?
|
Hospitalization | 6 | 2023 | 10808 | 0.100 |
Why?
|
Cell Count | 1 | 2016 | 1823 | 0.100 |
Why?
|
Interferon-gamma | 1 | 2020 | 3160 | 0.090 |
Why?
|
Autoantibodies | 2 | 2021 | 2113 | 0.090 |
Why?
|
Proto-Oncogene Proteins | 2 | 2015 | 4520 | 0.090 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2020 | 2570 | 0.090 |
Why?
|
Paraneoplastic Syndromes | 1 | 2013 | 156 | 0.090 |
Why?
|
Case-Control Studies | 5 | 2017 | 22222 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 2056 | 0.090 |
Why?
|
Immune Tolerance | 1 | 2020 | 2324 | 0.090 |
Why?
|
Cyclophosphamide | 1 | 2017 | 2228 | 0.090 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2210 | 0.090 |
Why?
|
Eosinophils | 1 | 2016 | 945 | 0.090 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 2845 | 0.090 |
Why?
|
Menorrhagia | 1 | 2010 | 59 | 0.090 |
Why?
|
Signal Transduction | 3 | 2020 | 23600 | 0.090 |
Why?
|
Graft vs Host Disease | 1 | 2023 | 3078 | 0.090 |
Why?
|
Drug Utilization | 1 | 2016 | 1187 | 0.080 |
Why?
|
Patient Selection | 2 | 2019 | 4255 | 0.080 |
Why?
|
25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2009 | 57 | 0.080 |
Why?
|
Postoperative Period | 1 | 2015 | 1816 | 0.080 |
Why?
|
New York City | 1 | 2012 | 733 | 0.080 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 1434 | 0.080 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2021 | 1480 | 0.080 |
Why?
|
Diagnostic Tests, Routine | 1 | 2015 | 790 | 0.080 |
Why?
|
Carcinoma, Renal Cell | 2 | 2021 | 3181 | 0.080 |
Why?
|
Anti-Inflammatory Agents | 2 | 2017 | 1808 | 0.080 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2021 | 2176 | 0.080 |
Why?
|
Odds Ratio | 3 | 2020 | 9649 | 0.080 |
Why?
|
Population Surveillance | 1 | 2019 | 2590 | 0.080 |
Why?
|
Disease Management | 2 | 2016 | 2535 | 0.080 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39194 | 0.080 |
Why?
|
Hospitals, General | 1 | 2013 | 802 | 0.080 |
Why?
|
Adrenal Cortex Hormones | 3 | 2022 | 1880 | 0.080 |
Why?
|
Anticoagulants | 2 | 2021 | 4862 | 0.080 |
Why?
|
Glomerulonephritis | 1 | 2010 | 332 | 0.070 |
Why?
|
Coronary Angiography | 1 | 2020 | 4494 | 0.070 |
Why?
|
Cerebral Hemorrhage | 1 | 2019 | 2648 | 0.070 |
Why?
|
Microscopy, Video | 1 | 2008 | 241 | 0.070 |
Why?
|
Shock, Septic | 1 | 2014 | 774 | 0.070 |
Why?
|
Sex Factors | 1 | 2021 | 10602 | 0.070 |
Why?
|
Consensus | 2 | 2024 | 3202 | 0.070 |
Why?
|
ras Proteins | 1 | 2013 | 1053 | 0.070 |
Why?
|
Ventilators, Mechanical | 1 | 2010 | 291 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7425 | 0.070 |
Why?
|
Connexin 43 | 1 | 2008 | 202 | 0.070 |
Why?
|
Checklist | 1 | 2014 | 848 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3645 | 0.070 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2011 | 499 | 0.070 |
Why?
|
Medical Staff, Hospital | 1 | 2011 | 601 | 0.070 |
Why?
|
Quality of Life | 1 | 2008 | 13461 | 0.070 |
Why?
|
Acute Coronary Syndrome | 1 | 2019 | 2184 | 0.070 |
Why?
|
Microscopy, Fluorescence | 2 | 2017 | 2627 | 0.070 |
Why?
|
New York | 1 | 2009 | 880 | 0.070 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4850 | 0.070 |
Why?
|
Students, Medical | 1 | 2019 | 1959 | 0.060 |
Why?
|
Age of Onset | 1 | 2013 | 3343 | 0.060 |
Why?
|
Reference Values | 1 | 2013 | 4908 | 0.060 |
Why?
|
Leiomyoma | 1 | 2010 | 643 | 0.060 |
Why?
|
Hematinics | 1 | 2008 | 282 | 0.060 |
Why?
|
Adolescent | 6 | 2021 | 88832 | 0.060 |
Why?
|
Resuscitation | 1 | 2010 | 679 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 4044 | 0.060 |
Why?
|
Double-Blind Method | 2 | 2021 | 12437 | 0.060 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1761 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2018 | 15398 | 0.060 |
Why?
|
Atrial Appendage | 1 | 2008 | 284 | 0.060 |
Why?
|
Cardiac Pacing, Artificial | 1 | 2008 | 881 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2014 | 2243 | 0.060 |
Why?
|
Blood Transfusion | 1 | 2010 | 1297 | 0.060 |
Why?
|
Mice, Knockout | 3 | 2020 | 14447 | 0.050 |
Why?
|
Veterans | 1 | 2017 | 2664 | 0.050 |
Why?
|
Massachusetts | 1 | 2016 | 8871 | 0.050 |
Why?
|
Up-Regulation | 1 | 2012 | 4137 | 0.050 |
Why?
|
Stroke Volume | 1 | 2017 | 5596 | 0.050 |
Why?
|
Disease Models, Animal | 3 | 2020 | 18294 | 0.050 |
Why?
|
Baclofen | 1 | 2023 | 121 | 0.050 |
Why?
|
Ultrasonography | 1 | 2016 | 5993 | 0.050 |
Why?
|
Immunity, Innate | 1 | 2014 | 3081 | 0.050 |
Why?
|
Digoxin | 1 | 2023 | 246 | 0.050 |
Why?
|
Linear Models | 1 | 2012 | 5876 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2019 | 7851 | 0.050 |
Why?
|
Boston | 1 | 2015 | 9338 | 0.050 |
Why?
|
Inflammation | 1 | 2021 | 10850 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2020 | 5849 | 0.050 |
Why?
|
Mice | 7 | 2020 | 81818 | 0.050 |
Why?
|
Nephrology | 1 | 2024 | 270 | 0.040 |
Why?
|
Quality Improvement | 1 | 2016 | 3853 | 0.040 |
Why?
|
Action Potentials | 1 | 2008 | 1838 | 0.040 |
Why?
|
Young Adult | 5 | 2021 | 59886 | 0.040 |
Why?
|
Kinetics | 1 | 2008 | 6274 | 0.040 |
Why?
|
Sclerosis | 1 | 2020 | 211 | 0.040 |
Why?
|
Vancomycin | 1 | 2023 | 504 | 0.040 |
Why?
|
Receptors, Chemokine | 1 | 2023 | 651 | 0.040 |
Why?
|
Receptors, Lysophosphatidic Acid | 1 | 2020 | 78 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12509 | 0.040 |
Why?
|
Adaptation, Physiological | 1 | 2006 | 1308 | 0.040 |
Why?
|
Antigens, CD1d | 1 | 2020 | 226 | 0.040 |
Why?
|
Cytokines | 1 | 2014 | 7421 | 0.040 |
Why?
|
Mycophenolic Acid | 1 | 2021 | 346 | 0.040 |
Why?
|
Candida | 1 | 2020 | 172 | 0.040 |
Why?
|
Time | 1 | 2021 | 550 | 0.040 |
Why?
|
Obesity | 1 | 2021 | 13075 | 0.040 |
Why?
|
Pregnancy | 1 | 2021 | 30258 | 0.040 |
Why?
|
Pentosyltransferases | 1 | 2018 | 63 | 0.040 |
Why?
|
Water-Electrolyte Balance | 1 | 2020 | 325 | 0.040 |
Why?
|
Prevalence | 2 | 2019 | 15839 | 0.040 |
Why?
|
Quinolinic Acid | 1 | 2018 | 67 | 0.040 |
Why?
|
Mortality | 2 | 2021 | 2904 | 0.040 |
Why?
|
Immunosuppressive Agents | 2 | 2024 | 4209 | 0.040 |
Why?
|
Immunoglobulins | 1 | 2021 | 852 | 0.040 |
Why?
|
Thrombophilia | 1 | 2021 | 308 | 0.040 |
Why?
|
Age Factors | 2 | 2020 | 18380 | 0.040 |
Why?
|
Troponin I | 1 | 2022 | 655 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 12976 | 0.040 |
Why?
|
Liposarcoma | 1 | 2020 | 288 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13451 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2024 | 20660 | 0.040 |
Why?
|
Primary Health Care | 1 | 2014 | 4736 | 0.040 |
Why?
|
Dietary Supplements | 1 | 2010 | 3426 | 0.040 |
Why?
|
Platelet Count | 1 | 2020 | 782 | 0.040 |
Why?
|
Candidiasis | 1 | 2020 | 371 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12807 | 0.040 |
Why?
|
Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2017 | 66 | 0.040 |
Why?
|
Survival Analysis | 2 | 2021 | 10070 | 0.030 |
Why?
|
Medical Records, Problem-Oriented | 1 | 2016 | 35 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15651 | 0.030 |
Why?
|
Leiomyosarcoma | 1 | 2020 | 423 | 0.030 |
Why?
|
Hyperthermia, Induced | 1 | 2020 | 415 | 0.030 |
Why?
|
Parotid Gland | 1 | 2017 | 177 | 0.030 |
Why?
|
Tryptophan | 1 | 2018 | 483 | 0.030 |
Why?
|
Niacinamide | 1 | 2018 | 419 | 0.030 |
Why?
|
Podocytes | 1 | 2020 | 391 | 0.030 |
Why?
|
Aftercare | 1 | 2021 | 911 | 0.030 |
Why?
|
Atrophy | 1 | 2020 | 1635 | 0.030 |
Why?
|
Heart | 1 | 2008 | 4414 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2017 | 18071 | 0.030 |
Why?
|
Electrocardiography | 1 | 2008 | 6404 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2354 | 0.030 |
Why?
|
Netherlands | 1 | 2019 | 2277 | 0.030 |
Why?
|
Proton Pump Inhibitors | 1 | 2019 | 553 | 0.030 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2020 | 790 | 0.030 |
Why?
|
Protein Folding | 1 | 2017 | 869 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2008 | 12769 | 0.030 |
Why?
|
Pneumonectomy | 1 | 2020 | 1128 | 0.030 |
Why?
|
Geriatric Assessment | 1 | 2021 | 1429 | 0.030 |
Why?
|
Heart Failure | 1 | 2017 | 11840 | 0.030 |
Why?
|
Saliva | 1 | 2017 | 851 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2021 | 14749 | 0.030 |
Why?
|
Societies, Medical | 1 | 2024 | 3956 | 0.020 |
Why?
|
United States Department of Veterans Affairs | 1 | 2017 | 934 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2024 | 26313 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2017 | 2587 | 0.020 |
Why?
|
Reperfusion Injury | 1 | 2017 | 1042 | 0.020 |
Why?
|
Risk Reduction Behavior | 1 | 2017 | 1123 | 0.020 |
Why?
|
Drug Combinations | 1 | 2017 | 2077 | 0.020 |
Why?
|
Cause of Death | 1 | 2021 | 3708 | 0.020 |
Why?
|
HIV Infections | 1 | 2017 | 17533 | 0.020 |
Why?
|
Metabolomics | 1 | 2020 | 1668 | 0.020 |
Why?
|
Mice, Inbred Strains | 1 | 2013 | 1770 | 0.020 |
Why?
|
Disease Progression | 2 | 2017 | 13631 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2021 | 4528 | 0.020 |
Why?
|
Ischemia | 1 | 2018 | 1909 | 0.020 |
Why?
|
Outpatients | 1 | 2017 | 1595 | 0.020 |
Why?
|
Aging | 1 | 2008 | 8731 | 0.020 |
Why?
|
Administration, Oral | 1 | 2017 | 4015 | 0.020 |
Why?
|
Physician Assistants | 1 | 2011 | 190 | 0.020 |
Why?
|
Patient Discharge | 1 | 2021 | 3461 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3850 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 8529 | 0.020 |
Why?
|
Data Collection | 1 | 2017 | 3318 | 0.020 |
Why?
|
Viral Load | 1 | 2017 | 3386 | 0.020 |
Why?
|
Nurse Practitioners | 1 | 2011 | 272 | 0.020 |
Why?
|
Venous Thromboembolism | 1 | 2021 | 1882 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2020 | 9550 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2017 | 22331 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2017 | 6309 | 0.020 |
Why?
|
Acute Disease | 1 | 2017 | 7232 | 0.020 |
Why?
|
Homeostasis | 1 | 2017 | 3336 | 0.020 |
Why?
|
Folic Acid | 1 | 2013 | 1339 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 5786 | 0.020 |
Why?
|
Cell Line | 1 | 2020 | 15543 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10729 | 0.010 |
Why?
|
Computer Simulation | 1 | 2017 | 6255 | 0.010 |
Why?
|
Proteomics | 1 | 2017 | 3910 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5526 | 0.010 |
Why?
|
Genotype | 1 | 2017 | 13024 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11868 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 9524 | 0.010 |
Why?
|
Models, Biological | 1 | 2017 | 9443 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 2017 | 4559 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 13039 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2017 | 11888 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2017 | 16047 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2015 | 20125 | 0.010 |
Why?
|
Internship and Residency | 1 | 2011 | 5946 | 0.010 |
Why?
|